Treatment of cancer‐associated venous thromboembolism : 12‐month outcomes of the placebo versus rivaroxaban randomisation of the SELECT‐D Trial. (SELECT‐D: 12m)

MLA

FD Richard Hobbs, et al. Treatment of Cancer‐associated Venous Thromboembolism : 12‐month Outcomes of the Placebo versus Rivaroxaban Randomisation of the SELECT‐D Trial. (SELECT‐D: 12m). Apr. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f8f2a6da4b9058ba2431e89133f14931&authtype=sso&custid=ns315887.

APA

FD Richard Hobbs, Janet A. Dunn, Danielle Hale, Ajay K. Kakkar, Stavros Petrou, Catherine Hill, Veronica Wilkie, Andrea Marshall, Anand Lokare, Mark Levine, Oliver Chapman, Annie M. Young, Mandy Maredza, Karen French, Azra Arif, Jenny Thirlwall, & Anthony Maraveyas. (2020). Treatment of cancer‐associated venous thromboembolism : 12‐month outcomes of the placebo versus rivaroxaban randomisation of the SELECT‐D Trial. (SELECT‐D: 12m).

Chicago

FD Richard Hobbs, Janet A. Dunn, Danielle Hale, Ajay K. Kakkar, Stavros Petrou, Catherine Hill, Veronica Wilkie, et al. 2020. “Treatment of Cancer‐associated Venous Thromboembolism : 12‐month Outcomes of the Placebo versus Rivaroxaban Randomisation of the SELECT‐D Trial. (SELECT‐D: 12m),” April. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f8f2a6da4b9058ba2431e89133f14931&authtype=sso&custid=ns315887.